Who Paid My Doc
A Phase 2B, Multi-Centre, Randomized, Partially Placebo-Controlled, DO
Research payments
$476,638
Through program year 2025, $476,638 in research payments was reported against A Phase 2B, Multi-Centre, Randomized, Partially Placebo-Controlled, DO, across 91 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $463,288 | 88 |
| 2024 | Research | $13,350 | 3 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
6 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Huy Nguyen San Jose, CA Named on 42 payments
- Maurizio Bonacini Eureka, CA Named on 16 payments
- Douglas Dieterich New York, NY Named on 13 payments
- Kuchikulla Reddy Philadelphia, PA Named on 13 payments
- Amanda Noska Minneapolis, MN Named on 6 payments
- Rajender Reddy Philadelphia, PA Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.